Etanercept for the treatment of refractory pyoderma gangrenosum: A brief series

Carlos A. Charles, Argentina Leon, Meggan R. Banta, Robert Kirsner

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background: Pyoderma gangrenosum (PG) is a rare ulcerative inflammatory condition of unknown etiology. Therapy for PG involves local wound care along with topical and systemic anti-inflammatory and other immunodulatory agents. Etanercept is one such immunomodulator with activity against the inflammatory cytokine, tumor necrosis factor. Objective: To evaluate the efficacy and safety of etanercept in the treatment of PG ulcers. Methods: A retrospective analysis was performed on seven patients with 11 refractory PG ulcers treated with subcutaneous injections of etanercept (25-50 mg twice weekly). Results: All seven patients with PG responded well to etanercept. Eight of the 11 ulcers (73%) completely healed with the mean time of (12.5 weeks), while the other three ulcers had marked reduction in size (within 8-18 weeks). Etanercept was well tolerated. No serious side-effects were reported. Only one patient discontinued the drug secondary to side-effects. Conclusion: Etanercept is an alternative treatment option for patients with refractory ulcers due to PG.

Original languageEnglish
Pages (from-to)1095-1099
Number of pages5
JournalInternational Journal of Dermatology
Volume46
Issue number10
DOIs
StatePublished - Oct 1 2007

Fingerprint

Pyoderma Gangrenosum
Ulcer
Therapeutics
Immunologic Factors
Subcutaneous Injections
Etanercept
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Cytokines
Safety
Wounds and Injuries
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Dermatology

Cite this

Etanercept for the treatment of refractory pyoderma gangrenosum : A brief series. / Charles, Carlos A.; Leon, Argentina; Banta, Meggan R.; Kirsner, Robert.

In: International Journal of Dermatology, Vol. 46, No. 10, 01.10.2007, p. 1095-1099.

Research output: Contribution to journalArticle

Charles, Carlos A. ; Leon, Argentina ; Banta, Meggan R. ; Kirsner, Robert. / Etanercept for the treatment of refractory pyoderma gangrenosum : A brief series. In: International Journal of Dermatology. 2007 ; Vol. 46, No. 10. pp. 1095-1099.
@article{58546915ffc34d689711f5062467402b,
title = "Etanercept for the treatment of refractory pyoderma gangrenosum: A brief series",
abstract = "Background: Pyoderma gangrenosum (PG) is a rare ulcerative inflammatory condition of unknown etiology. Therapy for PG involves local wound care along with topical and systemic anti-inflammatory and other immunodulatory agents. Etanercept is one such immunomodulator with activity against the inflammatory cytokine, tumor necrosis factor. Objective: To evaluate the efficacy and safety of etanercept in the treatment of PG ulcers. Methods: A retrospective analysis was performed on seven patients with 11 refractory PG ulcers treated with subcutaneous injections of etanercept (25-50 mg twice weekly). Results: All seven patients with PG responded well to etanercept. Eight of the 11 ulcers (73{\%}) completely healed with the mean time of (12.5 weeks), while the other three ulcers had marked reduction in size (within 8-18 weeks). Etanercept was well tolerated. No serious side-effects were reported. Only one patient discontinued the drug secondary to side-effects. Conclusion: Etanercept is an alternative treatment option for patients with refractory ulcers due to PG.",
author = "Charles, {Carlos A.} and Argentina Leon and Banta, {Meggan R.} and Robert Kirsner",
year = "2007",
month = "10",
day = "1",
doi = "10.1111/j.1365-4632.2007.03286.x",
language = "English",
volume = "46",
pages = "1095--1099",
journal = "International Journal of Dermatology",
issn = "0011-9059",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Etanercept for the treatment of refractory pyoderma gangrenosum

T2 - A brief series

AU - Charles, Carlos A.

AU - Leon, Argentina

AU - Banta, Meggan R.

AU - Kirsner, Robert

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Background: Pyoderma gangrenosum (PG) is a rare ulcerative inflammatory condition of unknown etiology. Therapy for PG involves local wound care along with topical and systemic anti-inflammatory and other immunodulatory agents. Etanercept is one such immunomodulator with activity against the inflammatory cytokine, tumor necrosis factor. Objective: To evaluate the efficacy and safety of etanercept in the treatment of PG ulcers. Methods: A retrospective analysis was performed on seven patients with 11 refractory PG ulcers treated with subcutaneous injections of etanercept (25-50 mg twice weekly). Results: All seven patients with PG responded well to etanercept. Eight of the 11 ulcers (73%) completely healed with the mean time of (12.5 weeks), while the other three ulcers had marked reduction in size (within 8-18 weeks). Etanercept was well tolerated. No serious side-effects were reported. Only one patient discontinued the drug secondary to side-effects. Conclusion: Etanercept is an alternative treatment option for patients with refractory ulcers due to PG.

AB - Background: Pyoderma gangrenosum (PG) is a rare ulcerative inflammatory condition of unknown etiology. Therapy for PG involves local wound care along with topical and systemic anti-inflammatory and other immunodulatory agents. Etanercept is one such immunomodulator with activity against the inflammatory cytokine, tumor necrosis factor. Objective: To evaluate the efficacy and safety of etanercept in the treatment of PG ulcers. Methods: A retrospective analysis was performed on seven patients with 11 refractory PG ulcers treated with subcutaneous injections of etanercept (25-50 mg twice weekly). Results: All seven patients with PG responded well to etanercept. Eight of the 11 ulcers (73%) completely healed with the mean time of (12.5 weeks), while the other three ulcers had marked reduction in size (within 8-18 weeks). Etanercept was well tolerated. No serious side-effects were reported. Only one patient discontinued the drug secondary to side-effects. Conclusion: Etanercept is an alternative treatment option for patients with refractory ulcers due to PG.

UR - http://www.scopus.com/inward/record.url?scp=34848822313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848822313&partnerID=8YFLogxK

U2 - 10.1111/j.1365-4632.2007.03286.x

DO - 10.1111/j.1365-4632.2007.03286.x

M3 - Article

C2 - 17910724

AN - SCOPUS:34848822313

VL - 46

SP - 1095

EP - 1099

JO - International Journal of Dermatology

JF - International Journal of Dermatology

SN - 0011-9059

IS - 10

ER -